Synthesis of middle–long–middle structured intralipids by biological catalysis and the evaluation of intralipids’ protective effect on liver injury rats

Abstract

Intralipid is wildly used in parenteral nutrition, providing energy and essential fatty acids for postoperative patients (Meguid et al., 1989).When the intralipid was injected into the vein, lipoprotein lipase was located in the endothelium, hydrolyzing triglyceride into sn-2 monoglyceride and fatty acid, which would be absorbed and metabolized by the skeletal muscle, cardiac muscle, liver cells, and adipose cells (Nguyen et al., 2008). The metabolic absorption and endogenous synthesis of majority lipids occur in the liver (Huang

Effects of Parenteral Nutrition with Amino Acid Alone and Amino Acid-Intralipid Combination on Vital Signs and Rate of Diuresis in ICU Patients

“…As for the liver enzymes, the findings of this study revealed that the administration of PN with amino acid-intralipid decreased the ALT, AST, and Bil, which was in line with the report of Liu et al The combination itself could further reduce ALT and AST (29). In addition, Navaratnarajah et al found that the children using SMOFlipid-intralipid had lower BL levels at the end of the study (30); however, Hsu et al established that amino acid administration had no effect on liver tests (31).…”

Synthesis of eicosapentaenoic acid‐enriched medium‐ and long‐chain triglyceride by lipase‐catalyzed transesterification: a novel strategy for clinical nutrition intervention

“…However, the physical mixture MCT/FO failed to improve the hydrolysis rate of EPA. If the MCT metabolic rate is too fast, this may result in a significant burden on the liver 10 . To overcome these shortcomings, an effective solution is to develop a medium‐ and long‐chain triglyceride (MLCT) containing both long‐chain fatty acid (LCFA) and medium‐chain fatty acid (MCFA) in a glycerol molecule, which may maintain stable energy supply and avoid ketone body poisoning in liver injury patients 10 .…”

“…If the MCT metabolic rate is too fast, this may result in a significant burden on the liver 10 . To overcome these shortcomings, an effective solution is to develop a medium‐ and long‐chain triglyceride (MLCT) containing both long‐chain fatty acid (LCFA) and medium‐chain fatty acid (MCFA) in a glycerol molecule, which may maintain stable energy supply and avoid ketone body poisoning in liver injury patients 10 . Due to its special triglyceride structure, MLCT is better able to maintain liver integrity and function compared to long‐chain triglyceride（LCT) and MCT/LCT 10 .…”

“…To overcome these shortcomings, an effective solution is to develop a medium‐ and long‐chain triglyceride (MLCT) containing both long‐chain fatty acid (LCFA) and medium‐chain fatty acid (MCFA) in a glycerol molecule, which may maintain stable energy supply and avoid ketone body poisoning in liver injury patients 10 . Due to its special triglyceride structure, MLCT is better able to maintain liver integrity and function compared to long‐chain triglyceride（LCT) and MCT/LCT 10 . Some reports indicated that MLCT was easy to digest and absorb due to its characteristic structures, especially when EPA is concentrated at the sn‐2 position, while MCFA is located at the sn‐1 and the sn‐3 positions 3,11 .…”